Navigation Links
Researchers' discovery may lead to hypertension treatment
Date:11/8/2007

compounds, has only been used for the analysis of purified compounds. Schroeder's approach allows NMR to identify compounds without isolating them, for example in a complex mixture such as partially fractionated urine. The technique revealed three completely new compounds, each of which was subsequently synthesized and injected into rats. The rats' urine was then monitored.

Two of the identified compounds, both derivatives of a common metabolite xanthurenic-acid, raised sodium levels in the rat's urine but kept potassium levels constant. Schroeder said that while aldosterone (which does the opposite) is a steroid hormone, this newly discovered molecule is structurally more similar to such amino acid-derived neurotransmitters as dopamine and serotonin and, therefore, may also play other roles in the body.

"Now, we want to know what other functions these compounds have and whether they directly influence blood pressure," said Schroeder.


'/>"/>

Contact: Blaine Friedlander
bpf2@cornell.edu
607-254-8093
Cornell University Communications
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Type 2 diabetes gene predisposes children to obesity 2New understanding of how to prevent destruction of a tumor suppressor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2UMass Boston Researcher Partner Develop Non Invasive Technique for Lead Testing in Humans 58234 1UMass Boston Researcher Partner Develop Non Invasive Technique for Lead Testing in Humans 58234 2UMass Boston Researcher Partner Develop Non Invasive Technique for Lead Testing in Humans 58234 3BEA Opens the Doors to the World at G20 Summit 58230 1BEA Opens the Doors to the World at G20 Summit 58230 2BEA Opens the Doors to the World at G20 Summit 58230 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 1Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 2Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 3Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 4Cardiologists Mobilize to Protect Quality Cardiac Care for Patients New Guarding Hearts Alliance 3A Heart Patients 26apos 3B Advocate in Congress 58226 5
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3